Cellular Origins, Resolution Therapeutics, and Cell and Gene Therapy Catapult formed a consortium awarded £1 million by Innovate UK to develop a fully automated, scalable manufacturing platform for cell and gene therapies. The initiative integrates robotics, digital technologies, and advanced bioreactors to enhance production efficiency, addressing current bottlenecks in delivering enough therapy doses to eligible patients globally. The platform aims to accelerate industry-wide adoption through GMP-compliant testbeds offering remote collaborator access.